Intervention to Enhance Cognitive Augmentation and Neuroplasticity (I-CAN)
Ohio State University Comprehensive Cancer Center
Summary
This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cognitive functioning, based on the brain's ability to reorganize and form new neural connections to accomplish tasks. I-CAN provides five core elements necessary for training the brain to create new neural connections including speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. The I-CAN intervention, when delivered before and after therapy, may help reduce the cognitive side effects of treatment in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.
Description
PRIMARY OBJECTIVE: I. To conduct a prospective single arm study of an Intervention to enhance Cognitive Augmentation and Neuroplasticity (I-CAN) program in 90 patients with relapsed B-cell hematologic malignancy receiving chimeric antigen receptor-T cell therapy (CAR-T). SECONDARY OBJECTIVES: I. To examine the neurocognitive change (Functional Assessment of Cancer Therapy-Cognition Perceived Cognitive Impairment \[FACT-Cog PCI\]; Montreal Cognitive Assessment \[MoCA\]) from baseline, following the I-CAN program at timepoint 2 (T2)-timepoint 5 (T5) in CAR T recipients. II. To examine the re…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients \>= 18 years of age * Diagnosed with relapsed/refractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL) * Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment * English literacy Exclusion Criteria: * Patients expected to live \< 6 months * Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery * Confirmed Alzheimer disease or other dementia * Previous central nervous system (CNS) radiation * Active intrathecal therapy at time of enr…
Interventions
- ProcedureBiospecimen Collection
Undergo collection of blood samples
- OtherCognitive Intervention
Participate in I-CAN training sessions
- OtherElectronic Health Record Review
Ancillary studies
- OtherSurvey Administration
Ancillary studies
Location
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio